BioSig Technologies, Inc. announced that it has received $0.597497 million in funding

BioSig Technologies, Inc. is a medical technology company focused on deciphering the body’s electrical signals, starting with heart rhythms. The Company’s product, the PURE EP Platform, a non-invasive class II device, provides real-time signal visualization allowing physicians to perform highly targeted cardiac ablation procedures. Integrating with existing systems in the EP lab, PURE EP is designed to pinpoint even the complex signals to maximize procedural success and efficiency. The PURE EP System is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures, such as environmental lab noise from other equipment, signal saturation, slow signal recovery, and inaccurate display of fractionated potentials. PURE EP is a signal processing platform that combines advanced hardware and software to address known challenges associated to signal acquisition, to enable electrophysiologists to see more signals and analyze them in real-time.